Technology Networks recently interviewed Alex Rosenberg, co-founder and CEO of Parse Biosciences to learn more about the company and its novel approach to single-cell sequencing.

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.

In this interview, Dr Andreas Bergmann discusses how the quantification of two pathway-specific biomarkers can support the diagnosis, monitoring and treatment of sepsis patients.

Here we summarize the webinar that was hosted by Monika Seidel Ph.D., in which she discussed detecting mutations with liquid biopsies in cancer diagnostics.

In this interview, Jim Mellon discusses some of the challenges that companies in the cultured meat sector face, how they are responding and what could be in store for the field over the next few years.

In this industry insights piece, we explore how gene therapies represent a rapidly growing new paradigm — both therapeutically and with respect to how they are managed within the larger scope of healthcare — and how this has wide-ranging impacts on several key areas, including regulation.

Technology Networks spoke with Dr Jan Hellemans, CTO and co-founder of CRO Biogazelle, as well as co-author of the MIQE guidelines, to learn why PCR-based technologies are the "workhorse" technologies for the company.

Verve Therapeutics is utilizing two of the biggest scientific breakthroughs of the twenty-first century – DNA sequencing and genome editing – to design a one-time treatment for lowering cholesterol.

2020 was an important year for proteomics. The COVID-19 global pandemic cast a spotlight on the field's clinical utility in the fight against a public health crisis, from which there are many lessons to be drawn that will undoubtedly influence the landscape of the field for years to come. Technology Networks spoke with Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the current state-of-play in proteomics.

Technology Networks spoke with Pierre-Louis Joffrin, corporate development officer at Mogrify, to learn more about the EpiMOGRIFY platform, the advantages of using a data-driven method to maintain cell identity and support cell conversion, and the implications this could have for the development of cell therapies.